BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arnott SJ, Duncan W, Gignoux M, Hansen HS, Launois B, Nygaard K, Parmar MK, Rousell A, Spilopoulos G, Stewart G. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev. 2005;19:CD001799. [PMID: 16235286 DOI: 10.1002/14651858.cd001799.pub2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Miccio JA, Oladeru OT, Yang J, Xue Y, Choi M, Zhang Y, Yoon H, Ryu S, Stessin AM. Neoadjuvant vs. adjuvant treatment of Siewert type II gastroesophageal junction cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. J Gastrointest Oncol 2016;7:403-10. [PMID: 27284473 DOI: 10.21037/jgo.2015.10.06] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
2 Sun L, Zhang H, Wu K. Esophageal Cancer: Current Options for Therapeutic Management. Gastrointest Tumors 2014;1:105-13. [PMID: 26674591 DOI: 10.1159/000362907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Shah RD, Cassano AD, Neifeld JP. Neoadjuvant therapy for esophageal cancer. World J Gastrointest Oncol 2014; 6(10): 403-406 [PMID: 25320656 DOI: 10.4251/wjgo.v6.i10.403] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
4 Thumallapally N, Meshref A, Mousa M, Hendawi M, Lan M, Salem AI, Forte F. Survival benefit of neoadjuvant versus adjuvant radiotherapy in lymph node positive esophageal cancer: a population based analysis. J Gastrointest Oncol 2017;8:825-32. [PMID: 29184686 DOI: 10.21037/jgo.2017.06.19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Baba Y, Watanabe M, Yoshida N, Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol 2014; 6(5): 121-128 [PMID: 24834142 DOI: 10.4251/wjgo.v6.i5.121] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
6 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Palmes D, Brüwer M, Bader FG, Betzler M, Becker H, Bruch HP, Büchler M, Buhr H, Ghadimi BM, Hopt UT, Konopke R, Ott K, Post S, Ritz JP, Ronellenfitsch U, Saeger HD, Senninger N; German Advanced Surgical Treatment Study Group. Diagnostic evaluation, surgical technique, and perioperative management after esophagectomy: consensus statement of the German Advanced Surgical Treatment Study Group. Langenbecks Arch Surg 2011;396:857-66. [PMID: 21713594 DOI: 10.1007/s00423-011-0818-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
9 Sun L, Zhao F, Zeng Y, Yi C. Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis. Med Sci Monit 2017;23:889-910. [PMID: 28214903 DOI: 10.12659/msm.903328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
10 Agranovich A, McGahan CE, Gurjal A. Long-term survivorship of esophageal cancer patients treated with radical intent. Can J Gastroenterol 2008;22:393-8. [PMID: 18414715 DOI: 10.1155/2008/231878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
11 Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012; 18(46): 6737-6746 [PMID: 23239911 DOI: 10.3748/wjg.v18.i46.6737] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
12 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
13 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
14 Berry MF. Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis. 2014;6 Suppl 3:S289-S297. [PMID: 24876933 DOI: 10.3978/j.issn.2072-1439.2014.03.11] [Cited by in F6Publishing: 57] [Reference Citation Analysis]
15 Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16(30): 3793-3803 [PMID: 20698042 DOI: 10.3748/wjg.v16.i30.3793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
16 Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ; SANO study group. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc 2015;4:e79. [PMID: 26121676 DOI: 10.2196/resprot.4320] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
17 Semrau R, Vallböhmer D, Hölscher AH, Müller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009;80:1035-41. [PMID: 19820906 DOI: 10.1007/s00104-009-1737-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
18 Xu Y, Yu X, Chen Q, Mao W. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol 2012;10:173. [PMID: 22920951 DOI: 10.1186/1477-7819-10-173] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
19 Matuschek C, Bölke E, Peiper M, Knoefel WT, Budach W, Erhardt A, Scherer A, Gerber PA, Buhren BA, Gattermann N, Baldus SE, Rusnak E, Shukla V, Orth K. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res 2011;16:265-74. [PMID: 21810561 DOI: 10.1186/2047-783x-16-6-265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
20 Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013;398:177-87. [PMID: 22971784 DOI: 10.1007/s00423-012-1001-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
21 Le Bras GF, Farooq MH, Falk GW, Andl CD. Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacol Res 2016;113:236-44. [PMID: 27565381 DOI: 10.1016/j.phrs.2016.08.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
22 Thomaschewski M, Hummel R, Petrova E, Knief J, Wellner UF, Keck T, Bausch D. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World J Gastroenterol 2018; 24(13): 1429-1439 [PMID: 29632424 DOI: 10.3748/wjg.v24.i13.1429] [Reference Citation Analysis]
23 Song Y, Tao G, Guo Q, Yang X, Zhu H, Wang W, Sun X. Survival benefit of surgery with radiotherapy vs surgery alone to patients with T2-3N0M0 stage esophageal adenocarcinoma. Oncotarget 2016;7:21347-52. [PMID: 26870996 DOI: 10.18632/oncotarget.7256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
24 Garg PK, Sharma J, Jakhetiya A, Goel A, Gaur MK. Preoperative therapy in locally advanced esophageal cancer. World J Gastroenterol 2016; 22(39): 8750-8759 [PMID: 27818590 DOI: 10.3748/wjg.v22.i39.8750] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
25 Ott K, Lordick F, Blank S, Büchler M. Gastric cancer: surgery in 2011. Langenbecks Arch Surg 2011;396:743-58. [PMID: 21234760 DOI: 10.1007/s00423-010-0738-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
26 Burmeister BH. Role of radiotherapy in the pre-operative management of carcinoma of the esophagus. World J Gastrointest Oncol 2015; 7(1): 1-5 [PMID: 25610538 DOI: 10.4251/wjgo.v7.i1.1] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
27 Li J, Ma S. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer. Thorac Cancer 2021;12:2293-9. [PMID: 34254738 DOI: 10.1111/1759-7714.14069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Buergy D, Lohr F, Baack T, Siebenlist K, Haneder S, Michaely H, Wenz F, Boda-Heggemann J. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy. Radiat Oncol. 2012;7:192. [PMID: 23157945 DOI: 10.1186/1748-717x-7-192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
29 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
30 Huang B, Shi H, Gong X, Yu J, Xiao C, Zhou B, Liang Z, Li X. Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma. J Gastrointest Oncol 2021;12:2013-21. [PMID: 34790369 DOI: 10.21037/jgo-21-610] [Reference Citation Analysis]